Actuate Therapeutics, Inc. (ACTU)

Actuate Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	13.52	2.96	20.45
Cash & Short-Term Investments	13.52	2.96	20.45
Cash Growth	-33.87%	-85.53%	-
Prepaid Expenses	0.74	0.04	0.03
Total Current Assets	14.26	3	20.48
Total Assets	14.26	3	20.48
Accounts Payable	2.33	3.42	2.13
Accrued Expenses	6.17	3.5	2.21
Total Current Liabilities	8.5	6.92	4.34
Other Long-Term Liabilities	0.41	0.54	0.49
Total Liabilities	8.9	7.46	4.84
Common Stock	0	0	0
Additional Paid-In Capital	131.29	5.47	5.04
Retained Earnings	-125.93	-105.09	-80.35
Total Common Equity	5.36	-99.63	-75.31
Shareholders' Equity	5.36	-4.46	15.65
Total Liabilities & Equity	14.26	3	20.48
Net Cash (Debt)	13.52	2.96	20.45
Net Cash Growth	-33.87%	-85.53%	-
Net Cash Per Share	3.50	2.06	16.89
Filing Date Shares Outstanding	19.53	1.69	1.21
Total Common Shares Outstanding	19.53	1.69	1.21
Working Capital	5.77	-3.93	16.14
Book Value Per Share	0.27	-58.93	-62.21
Tangible Book Value	5.36	-99.63	-75.31
Tangible Book Value Per Share	0.27	-58.93	-62.21

Source: S&P Capital IQ. Standard template. Financial Sources.